Adamax Preclinical

What It Is

Adamax is the community / vendor name most commonly used for N-Acetyl Semax Amidate (NASA) — a chemical derivative of the Russian ACTH-analog nootropic Semax. Semax itself (Met-Glu-His-Phe-Pro-Gly-Pro, MEHFPGP) is a seven-amino-acid peptide derived from the N-terminal region of adrenocorticotropic hormone (ACTH). It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and at Moscow State University, and has been marketed in Russia as Semaks (Семакс) since the 1990s for stroke, cognitive impairment, and asthenia.

Adamax modifies Semax at both ends. The N-terminal methionine is acetylated (Ac-Met...) to block aminopeptidase-mediated degradation; the C-terminal proline is amidated (...Pro-NH₂) to block carboxypeptidase cleavage. Parent Semax is already unusually stable because its C-terminal Pro-Gly-Pro motif is inherently resistant to most peptidases, but parent Semax still has a central nervous system duration of action measured in tens of minutes to a few hours. The double-blocked Adamax analog has been reported by Russian investigators and secondary reviewers to extend biochemical half-life and CNS exposure substantially.

In the commercial nootropic hierarchy, the compound family is often described as: Semax → N-Acetyl Semax (single N-terminal blocked) → N-Acetyl Semax Amidate / Adamax (both ends blocked). Each modification is claimed to increase metabolic stability, duration of BDNF elevation, and in some cases BBB penetration. The published evidence supporting each successive analog is progressively thinner — Semax itself has decades of Russian clinical data, N-Acetyl Semax has a smaller preclinical database, and the doubly-blocked Adamax form has essentially only preclinical evidence with heavy reliance on analogical reasoning from the parent.

Users should also be aware that "Adamax" is a vendor-chosen trade name that overlaps with unrelated pharmaceutical products in other therapeutic areas. In the peptide / nootropic context, the name refers specifically to N-Acetyl Semax Amidate.

Mechanism of Action

Mechanistic work on Adamax is largely by-analogy to parent Semax with modest direct data. The mechanistic picture below reflects Semax-family biology as published by the Myasoedov / Grivennikov / Dolotov laboratories in Moscow plus a small number of Western citing reports.

• Hippocampal BDNF / NGF upregulation — Semax treatment rapidly increases BDNF and NGF mRNA and protein in rat hippocampus and basal forebrain (Dolotov et al., Doklady Biol Sci 2006; PMID 16927610). The doubly-protected Adamax analog is reported in Russian preclinical work to achieve proportionally larger and longer-lasting BDNF elevation by virtue of its extended CNS exposure, though the comparative head-to-head human data does not exist.
• TrkB / MAPK / ERK signaling — BDNF acts through TrkB receptor tyrosine kinase, activating the Ras-Raf-MEK-ERK and PI3K-Akt cascades that drive long-term potentiation (LTP), dendritic spine growth, and synaptic remodeling. Chronic ACTH-4-10 analog exposure in rodents increases markers of hippocampal plasticity.
• Enkephalinase (neprilysin) inhibition — Semax and its analogs appear to inhibit the enkephalin-degrading enzyme neprilysin, indirectly potentiating endogenous opioid tone. This may underlie some of the reported analgesic / mood-modulating properties of the family.
• Melanocortin MC3 / MC4 receptor modulation — Because the parent ACTH(4-10) fragment retains melanocortin-system activity, Semax-family peptides engage MC3/MC4 receptors in the CNS. These receptors are involved in attention, motivation, and stress-reactive HPA-axis modulation. Effect on peripheral MC1/MC2 is attenuated.
• Dopaminergic / serotonergic tone — Preclinical Russian work has described Semax-induced modulation of striatal dopamine and cortical serotonin — effects broadly consistent with the compound's reported motivational and attentional properties.
• Neuroprotection in ischemia — In rat middle-cerebral-artery occlusion (MCAO) stroke models, Semax and its longer-duration analogs reduce infarct volume, protect hippocampal CA1 pyramidal neurons, and preserve neurologic outcome scores (Shadrina et al., Peptides; Stavchansky et al.).
• Dual-terminal protease resistance — Acetylation and amidation together confer resistance to both aminopeptidases and carboxypeptidases, the two major peptidase classes that limit peptide half-life in plasma and nasal mucosa. This is the structural basis for the longer duration claim.
• Intranasal CNS delivery — Like parent Semax, Adamax is administered intranasally, taking advantage of direct olfactory and trigeminal nerve pathways that bypass the blood-brain barrier to some extent. Published ACTH(4-10) analog intranasal dosimetry shows CNS concentrations achievable at very low systemic exposure.

What the Research Shows

• Parent Semax clinical base — Parent Semax is approved in Russia (registered 1996–1997) for ischemic stroke, transient ischemic attack, cognitive impairment, and optic nerve disorders. Russian-language randomized trials in these indications form the clinical backbone of the Semax family. Independent Western replication is limited.
• BDNF elevation (preclinical) — Semax increases hippocampal BDNF mRNA and protein in rats; N-acetyl and doubly-protected analogs show proportionally larger and longer-lasting elevations in the same assays.
• Cognitive testing (preclinical) — Rodent learning and memory tasks (Morris water maze, passive avoidance, radial arm maze) show improved acquisition and retention with Semax-family peptides. The longer-duration analogs produce effects at lower doses or with less-frequent dosing.
• Stroke models — MCAO models in rats and gerbils demonstrate reduced infarct volume, preserved CA1 neurons, and improved functional outcomes. This preclinical stroke signal is the basis for the parent compound's Russian clinical stroke indication.
• Anxiolytic / anti-depressant signal — Forced-swim, elevated-plus-maze, and open-field tests in rodents show anxiolytic-like and antidepressant-like effects. Russian clinical reports extend this to human asthenia and post-stroke depression.
• Optic nerve / retinal preservation — Russian ophthalmology trials report benefit in optic nerve atrophy and vascular retinopathy, leading to a niche clinical indication for Semax eye-drops.
• Addiction / withdrawal — Some Russian work has explored Semax-family effects on opioid withdrawal severity — coherent with the enkephalinase inhibition mechanism.
• Head-to-head Adamax vs Semax — Formal head-to-head clinical comparisons do not exist. Pharmacokinetic comparison data is limited to preclinical analogs of analogs, not to the specific NASA compound sold as Adamax.

Human Data

There is no published Western human clinical trial of Adamax (N-Acetyl Semax Amidate) as such. The parent Semax compound has decades of Russian clinical use and multiple Russian-language RCTs for stroke, post-stroke cognitive recovery, asthenia, and optic nerve disorders; those are the human evidence base on which Adamax claims rest.

• Parent Semax — Russian stroke trials — Multiple Russian multicenter studies in acute ischemic stroke (intranasal Semax add-on to standard of care) report improved NIHSS and Barthel Index outcomes vs placebo. These are published primarily in Russian journals with limited independent verification.
• Parent Semax — asthenia / cognitive fog — Smaller Russian trials in neurasthenia and post-viral cognitive impairment report benefit on subjective and neuropsychological endpoints.
• Parent Semax — ophthalmology — Russian optic-nerve-atrophy and vascular-retinopathy studies support the compound's niche eye-drop use.
• N-Acetyl Semax / Adamax — no published human trials — ClinicalTrials.gov shows no registered Western trial. The Russian State Registry of Medicines lists approved Semax products (nasal drops) but does not separately register Adamax.
• Community use — Nootropic community reports describe subjective cognitive stimulation, improved focus, reduced mental fatigue, and occasional mild restlessness / insomnia when dosed late in the day. These are uncontrolled anecdotes, not clinical evidence.

Dosing from the Literature

The following doses reflect parent Semax clinical dosing (Russian labeling) plus community dosing for the longer-duration analogs. No FDA-approved dose exists for Adamax in any jurisdiction.

Reconstitution & Storage

Adamax is typically supplied as lyophilized powder in 10 mg or 30 mg vials or as a pre-mixed nasal-spray solution.

• Reconstitution — Slow addition of bacteriostatic water or sterile saline down the wall of the vial; swirl, do not shake. Should yield clear colorless solution.
• Storage — Lyophilized powder stable at 2–8°C long-term (or room temperature short-term out of light). Reconstituted nasal solution: refrigerate, use within 21–28 days.
• Delivery — Tilt head slightly back, deliver into nostril, breathe gently inward without forcing. Alternate nostrils between doses. Avoid blowing nose for 15+ minutes post-dose.
• Storage discipline — Do not freeze reconstituted solution. Discard if cloudy or discolored.

→ Use the Kalios Dosing Calculator

Side Effects & Risks

• Nasal irritation — Mild stinging, burning, or nasal drip during or after administration. Usually dose-dependent.
• Overstimulation / insomnia — The extended duration of the doubly-protected analog means later-in-day dosing has a stronger potential to delay sleep onset. Morning / early-afternoon dosing reduces this risk.
• Headache — Occasionally reported; typically mild and transient.
• Mood / anxiety — Some users describe mild agitation or elevated anxiety, particularly at higher doses. Others report the opposite — reduced anxiety and improved stress tolerance (consistent with anxiolytic signal in preclinical studies).
• Hair / skin changes (anecdotal) — Rare reports of temporary hair shedding with chronic high-dose use. Not a confirmed pharmacological effect; biological plausibility is unclear.
• Cardiac / adrenal theoretical concerns — As an ACTH-analog, any residual HPA-axis activity is theoretically possible, although the 4-10 fragment design specifically removed classical cortisol-stimulating activity. Adrenal-axis monitoring in long-term users is prudent.
• Pregnancy and lactation — No human safety data. Do not use.
• Drug interactions — No well-characterized interactions. Theoretical caution with other dopaminergic stimulants (additive restlessness) and with MAO inhibitors.
• Purity risk — Peptide research-chemical quality varies. Third-party HPLC and mass-spec confirmation is recommended. Some vendors have been shown to sell mislabeled product in the Semax / Selank family.
• Long-term safety — No published chronic-dosing human safety database for the doubly-protected analog. Parent Semax has decades of Russian use without major safety signals, but Adamax is not identical to parent Semax.

Bloodwork & Monitoring

• Baseline CMP and CBC — Liver, kidney, and hematological function before starting.
• Morning cortisol / ACTH — For longer-term users, baseline and follow-up HPA-axis screening is reasonable given the ACTH-analog origin of the family.
• Thyroid panel — Baseline and periodic, particularly if neurologic / fatigue symptoms emerge.
• Sleep tracking — Subjective or device-based sleep quality monitoring catches overstimulation early.
• Mood and anxiety inventory — Standardized brief scales (PHQ-9, GAD-7) at baseline and every 2–4 weeks during use.
• Cognitive testing — Optional: baseline and post-cycle computerized cognition testing (e.g., Cambridge Brain Sciences, NeuroTrax) for subjective-objective correlation.

Commonly Stacked With

→ Check compound compatibility in the Stack Builder

Regulatory Status

Related Compounds

People researching Adamax often also look at these:

Next Steps

Key References

1. Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, Dubynina EV, Novosadova EV, Andreeva LA, Alfeeva LY, Kamensky AA, Grivennikov IA, Engele J, Myasoedov NF. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54-60. PMID: 16996037.
2. Dolotov OV, Karpenko EA, Seredenina TS, Inozemtseva LS, Levitskaya NG, Kamensky AA, Andreeva LA, Alfeeva LY, Nagaev IY, Zolotarev YA, Grivennikov IA, Engele J, Myasoedov NF. Semax, an analog of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. J Neurochem. 2006;97 Suppl 1:82-86. PMID: 16635254.
3. Ashmarin IP, Nezavibatko VN, Levitskaya NG, Koshelev VB, Kamensky AA. Design and investigation of an ACTH(4-10) analog lacking D-amino acids and hydrophobic radicals. Neurosci Res Commun. 1995;16(2):105-112.
4. Kaplan AYa, Kochetova AG, Nezavibathko VN, Rjasina TV, Ashmarin IP. Synthetic ACTH analogue Semax displays nootropic-like activity in humans. Neurosci Res Commun. 1996;19(2):115-123.
5. Medvedeva EV, Dmitrieva VG, Povarova OV, Limborska SA, Skvortsova VI, Myasoedov NF, Dergunova LV. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014;15:228. PMID: 24661604.
6. Shadrina MI, Dolotov OV, Grivennikov IA, Slominsky PA, Andreeva LA, Inozemtseva LS, Limborska SA, Myasoedov NF. Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog. Neurosci Lett. 2001;308(2):115-118. PMID: 11457575.
7. Stavchansky VV, Yuzhakov VV, Botsina AY, Skvortsova VI, Bondurko LN, Tsyganova MG, Limborska SA, Myasoedov NF, Dergunova LV. The effect of Semax and its C-end peptide PGP on the morphology and proliferative activity of rat brain cells during experimental ischemia: a pilot study. J Mol Neurosci. 2011;45(2):177-185. PMID: 21384125.
8. Gusev EI, Skvortsova VI, Miasoedov NF, Nezavibatko VN, Zhuravleva EIu, Vanichkin AV. Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zh Nevrol Psikhiatr Im S S Korsakova. 1997;97(6):26-34. PMID: 9311894.
9. Potaman VN, Antonova LV, Dubynin VA, Zaitzev DA, Kamensky AA, Myasoedov NF, Nezavibatko VN. Entry of the synthetic ACTH(4-10) analogue into the rat brain following intravenous injection. Neurosci Lett. 1991;127(1):133-136. PMID: 1881613.
10. Levitskaya NG, Sebentsova EA, Andreeva LA, Alfeeva LY, Kamenskii AA, Myasoedov NF. Comparative study of the physiological effects of semax on the central nervous system. Neurosci Behav Physiol. 2002;32(4):355-360. PMID: 12243262.
11. Myasoedov NF, Skvortsova VI, Nasonov EL, Zhuravleva EY, Grivennikov IA, Arsenyeva EL, Sukhanov IV. Studies of the mechanism of action of Semax in acute hypoxia of the brain. Zh Nevrol Psikhiatr Im S S Korsakova. 1999;99(5):15-19. PMID: 10358599.
12. Romanova GA, Silachev DN, Shakova FM, Kvashennikova YuN, Viktorov IV, Shram SI, Myasoedov NF. Neuroprotective and antiamnesic effects of semax during experimental ischemic infarction of the cerebral cortex. Bull Exp Biol Med. 2006;142(6):663-666. PMID: 17603685.